Drug intelligence / Profile preview

DX-643

Development stage: Preclinical
Lead developer: DermaXon
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

DX-643 is a proteolysis-targeting chimera (PROTAC) drug candidate developed by DermaXon LLC. It is in preclinical development for the treatment of autoinflammatory diseases, which are disorders characterized by abnormal activation of the innate immune system. As a PROTAC, DX-643 is designed to induce targeted degradation of specific disease-related proteins within cells, thereby modulating pathological immune responses. The precise molecular target and mechanism have not been publicly disclosed as of the latest available update[1][7].

Beyond the preview

Go deeper on DX-643.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DX-643.

Explore the full profile